1. Home
  2. ATEX vs DRUG Comparison

ATEX vs DRUG Comparison

Compare ATEX & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anterix Inc.

ATEX

Anterix Inc.

HOLD

Current Price

$22.03

Market Cap

404.5M

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$86.50

Market Cap

364.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATEX
DRUG
Founded
1997
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Pharmaceuticals and Biotechnology
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
404.5M
364.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ATEX
DRUG
Price
$22.03
$86.50
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$58.50
$83.00
AVG Volume (30 Days)
235.6K
150.8K
Earning Date
11-12-2025
12-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
5.13
N/A
Revenue
$5,925,000.00
N/A
Revenue This Year
$6.22
N/A
Revenue Next Year
$4.31
N/A
P/E Ratio
$4.48
N/A
Revenue Growth
5.67
N/A
52 Week Low
$17.58
$23.18
52 Week High
$42.91
$93.40

Technical Indicators

Market Signals
Indicator
ATEX
DRUG
Relative Strength Index (RSI) 58.72 70.80
Support Level $19.55 $69.12
Resistance Level $23.29 $93.40
Average True Range (ATR) 0.86 7.05
MACD 0.25 1.56
Stochastic Oscillator 64.75 78.69

Price Performance

Historical Comparison
ATEX
DRUG

About ATEX Anterix Inc.

Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: